l-Carnitine intake prevents irregular feeding-induced obesity and lipid metabolism disorder

Wu, Tao; Guo, Anqi; Shu, Qingyu; Qi, Yangjian; Kong, Ying; Sun, Zhi-Ping; Sun, Siyuan; Fu, Zhengwei

doi:10.1016/j.gene.2014.10.040

Cited by 26 publications

(18 citation statements)

References 38 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another interesting observation in this study is that L‐carnitine significantly prevented body weight gain in KK‐A y mice during HFD feeding (Fig. a), which is consistent with previous reports using mouse models fed HFD and irregular diets . The reduction of body weight by L‐carnitine has also been reported in obese patients with metabolic syndrome and polycystic ovary syndrome .…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

L‐carnitine prevents metabolic steatohepatitis in obese diabetic KK‐A^y mice

Kon

Ikejima

Morinaga

et al. 2016

Hepatology Research

View full text Add to dashboard Cite

Aim: Pharmacological treatment for metabolic syndromerelated non-alcoholic steatohepatitis has not been established. We investigated the effect of L-carnitine, an essential substance for β-oxidation, on metabolic steatohepatitis in mice. Methods:Male KK-A y mice were fed a high-fat diet (HFD) for 8 weeks, with supplementation of L-carnitine (1.25 mg/mL) in drinking water for the latter 4 weeks.Results: Serum total carnitine levels were decreased following HFD feeding, whereas the levels were reversed almost completely by L-carnitine supplementation. In mice given L-carnitine, exacerbation of hepatic steatosis and hepatocyte apoptosis was markedly prevented even though HFD feeding was continued. Body weight gain, as well as hyperlipidemia, hyperglycemia, and hyperinsulinemia, following HFD feeding were also significantly prevented in mice given L-carnitine. High-fat diet feeding elevated hepatic expression levels of carnitine palmitoyltransferase 1A mRNA; however, production of β-hydroxybutyrate in the liver was not affected by HFD alone.In contrast, L-carnitine treatment significantly increased hepatic β-hydroxybutyrate contents in HFD-fed mice. L-carnitine also blunted HFD induction in sterol regulatory element binding protein-1c mRNA in the liver. Furthermore, L-carnitine inhibited HFD-induced serine phosphorylation of insulin receptor substrate-1 in the liver. L-carnitine decreased hepatic free fatty acid content in 1 week, with morphological improvement of swollen mitochondria in hepatocytes, and increases in hepatic adenosine 5'-triphosphate content.Conclusions: L-carnitine ameliorates steatohepatitis in KK-A y mice fed an HFD, most likely through facilitating mitochondrial β-oxidation, normalizing insulin signals, and inhibiting de novo lipogenesis in the liver. It is therefore postulated that supplementation of L-carnitine is a promising approach for prevention and treatment of metabolic syndrome-related non-alcoholic steatohepatitis.

show abstract

Section: Discussionsupporting

confidence: 92%

“…1a), which is consistent with previous reports using mouse models fed HFD 34 and irregular diets. 35 The reduction of body weight by L-carnitine has also been reported in obese patients with metabolic syndrome 36 and polycystic ovary syndrome. 37 Moreover, L-carnitine improved hyperlipidemia, hyperglycemia, and hyperinsulinemia (Figs.…”

Section: Discussionmentioning

confidence: 89%

L‐carnitine prevents metabolic steatohepatitis in obese diabetic KK‐A^y mice

Kon

Ikejima

Morinaga

et al. 2016

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Considering the role of LC in ␤-oxidation, studies have suggested the potential use of LC for the treatment of lipotoxicity, under pathological conditions [37], including steatohepatitis [38]. LC has the ability to scavenge free radicals [39,40] and protect hepatocytes against oxidative damages caused under different conditions including ethanol intoxication [41], obesity [42], and carcinoma [43]. Here, we observed that LC counteracts COX imbalance caused by MCDD ( Fig.…”

Section: Discussionmentioning

confidence: 55%

L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet

Mollica

Senesi

Codella

et al. 2020

Digestive and Liver Disease

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disorder. NAFLD, associated lipotoxicity, fibrosis, oxidative stress, and altered mitochondrial metabolism, is responsible for systemic inflammation, which contributes to organ dysfunction in extrahepatic tissues, including the heart. We investigated the ability of L-carnitine (LC) to oppose the pathogenic mechanisms underlying NAFLD progression and associated heart dysfunction, in a mouse model of methionine-choline-deficient diet (MCDD). Mice were divided into three groups: namely, the control group (CONTR) fed with a regular diet and two groups fed with MCDD for 6 weeks. In the last 3 weeks, one of the MCDD groups received LC (200 mg/kg each day) through drinking water (MCDD + LC). The hepatic lipid accumulation and oxidative stress decreased after LC supplementation, which also reduced hepatic fibrosis via modulation of ␣-smooth muscle actin (␣SMA), peroxisome-activated receptor gamma (PPAR␥), and nuclear factor kappa B (Nf B) expression. LC ameliorated systemic inflammation, mitigated cardiac reactive oxygen species (ROS) production, and prevented fibrosis progression by acting on signal transducer and activator of transcription 3 (STAT3), extracellular signal-regulated kinase 1-2 (ERK1-2), and ␣SMA. This study confirms the existence of a relationship between fatty liver disease and cardiac abnormalities and highlights the role of LC in controlling liver oxidative stress, steatosis, fibrosis, and NAFLD-associated cardiac dysfunction.

show abstract

“…We thought that it might have correlated with the different food or different lifestyle. Study also showed that the time-delayed pattern of eating can induce adiposity and lipid metabolic disorders [ 31 ]. Food ingredients act also as antiobesity agents [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Traditional Chinese Medicine for Metabolic Syndrome via TCM Pattern Differentiation: Tongue Diagnosis for Predictor

Lee

2016

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Metabolic syndrome is a morbid condition, which is manifested by central obesity, abnormal glucose tolerance, lipodystrophy, and hypertension. Traditional Chinese medicine (TCM) clarifies that obesity is classified as phlegm-dampness. It is often accompanied with qi stagnation and blood stasis. One hundred and two overweight adults, who did not receive lipid-lowering drugs, were enrolled for analysis. The exclusion criteria were adults having malignancy disease, DM, and renal disease or who were pregnant or lactating. The study was divided into two groups: metabolic syndrome group (MetS) and nonmetabolic syndrome group (nMetS). The modern tongue analysis and heart rate variability devices for data analysis and Council on Nutrition Appetite Questionnaire (CNAQ) for appetite evaluation were used. Obesity patients with metabolic syndrome obviously have lower CNAQ score. The 6 items of CNAQ between two groups have significant difference in variation (P < 0.001). The nMetS average was above 28 scores (96%) and the MetS was all in 17–28 scores. The tongue appearance showed that MetS group have white coating different from the nMetS group with white and yellow coating (P < 0.05). However the HRV is not different from nMetS group significantly. Our results try to explore the relationship between the TCM pattern, nutrition appetite, and heart rate variability in metabolic syndrome patients.

show abstract

l-Carnitine intake prevents irregular feeding-induced obesity and lipid metabolism disorder

Cited by 26 publications

References 38 publications

L‐carnitine prevents metabolic steatohepatitis in obese diabetic KK‐A^y mice

L‐carnitine prevents metabolic steatohepatitis in obese diabetic KK‐A^y mice

L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet

Traditional Chinese Medicine for Metabolic Syndrome via TCM Pattern Differentiation: Tongue Diagnosis for Predictor

Contact Info

Product

Resources

About

l-Carnitine intake prevents irregular feeding-induced obesity and lipid metabolism disorder

Cited by 26 publications

References 38 publications

L‐carnitine prevents metabolic steatohepatitis in obese diabetic KK‐Ay mice

L‐carnitine prevents metabolic steatohepatitis in obese diabetic KK‐Ay mice

L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet

Traditional Chinese Medicine for Metabolic Syndrome via TCM Pattern Differentiation: Tongue Diagnosis for Predictor

Contact Info

Product

Resources

About

L‐carnitine prevents metabolic steatohepatitis in obese diabetic KK‐A^y mice

L‐carnitine prevents metabolic steatohepatitis in obese diabetic KK‐A^y mice